Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy BT, Eustace AJ. Elster N, et al. Among authors: cremona m. Breast Cancer Res Treat. 2015 Jan;149(2):373-83. doi: 10.1007/s10549-014-3239-5. Epub 2014 Dec 21. Breast Cancer Res Treat. 2015. PMID: 25528022
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. Stordal B, et al. Among authors: cremona m. Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31. Mol Oncol. 2013. PMID: 23415752 Free PMC article.
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.
Salvucci M, Würstle ML, Morgan C, Curry S, Cremona M, Lindner AU, Bacon O, Resler AJ, Murphy ÁC, O'Byrne R, Flanagan L, Dasgupta S, Rice N, Pilati C, Zink E, Schöller LM, Toomey S, Lawler M, Johnston PG, Wilson R, Camilleri-Broët S, Salto-Tellez M, McNamara DA, Kay EW, Laurent-Puig P, Van Schaeybroeck S, Hennessy BT, Longley DB, Rehm M, Prehn JH. Salvucci M, et al. Among authors: cremona m. Clin Cancer Res. 2017 Mar 1;23(5):1200-1212. doi: 10.1158/1078-0432.CCR-16-1084. Epub 2016 Sep 20. Clin Cancer Res. 2017. PMID: 27649552
BCL-2 system analysis identifies high-risk colorectal cancer patients.
Lindner AU, Salvucci M, Morgan C, Monsefi N, Resler AJ, Cremona M, Curry S, Toomey S, O'Byrne R, Bacon O, Stühler M, Flanagan L, Wilson R, Johnston PG, Salto-Tellez M, Camilleri-Broët S, McNamara DA, Kay EW, Hennessy BT, Laurent-Puig P, Van Schaeybroeck S, Prehn JHM. Lindner AU, et al. Among authors: cremona m. Gut. 2017 Dec;66(12):2141-2148. doi: 10.1136/gutjnl-2016-312287. Epub 2016 Sep 23. Gut. 2017. PMID: 27663504
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ. Toomey S, et al. Among authors: cremona m. Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782. Oncotarget. 2016. PMID: 27776352 Free PMC article.
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ. O'Shea J, et al. Among authors: cremona m. Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156708 Free PMC article.
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Milewska M, Cremona M, Morgan C, O'Shea J, Carr A, Vellanki SH, Hopkins AM, Toomey S, Madden SF, Hennessy BT, Eustace AJ. Milewska M, et al. Among authors: cremona m. Ther Adv Med Oncol. 2018 Jan 9;10:1758834017746040. doi: 10.1177/1758834017746040. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29383036 Free PMC article.
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, Carr A, Kennedy S, Furney S, Mezynski J, Breathhnach O, Morris P, Grogan L, Hill A, Kennedy S, Crown J, Gallagher W, Hennessy B, Eustace A. Elster N, et al. Among authors: cremona m. Ther Adv Med Oncol. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30023006 Free PMC article.
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Coté D, Eustace A, Toomey S, Cremona M, Milewska M, Furney S, Carr A, Fay J, Kay E, Kennedy S, Crown J, Hennessy B, Madden S. Coté D, et al. Among authors: cremona m. PLoS One. 2018 Aug 2;13(8):e0200996. doi: 10.1371/journal.pone.0200996. eCollection 2018. PLoS One. 2018. PMID: 30071039 Free PMC article. Clinical Trial.
101 results